

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Alebund Pharmaceuticals (Jiangsu) Limited

禮邦醫藥(江蘇)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 09637)

VOLUNTARY ANNOUNCEMENT FIRST PARTICIPANT RANDOMIZED AND DOSED IN GLOBAL PHASE IIb MULTI-REGIONAL CLINICAL TRIAL OF AP306 FOR HYPERPHOSPHATEMIA IN PATIENTS RECEIVING MAINTENANCE HEMODIALYSIS

This announcement is made by Alebund Pharmaceuticals (Jiangsu) Limited (the “**Company**,” together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of AP306 in patients with hyperphosphatemia receiving maintenance hemodialysis (ClinicalTrials.gov identifier: NCT06712654) (the “**Phase IIb Trial**”). The Phase IIb Trial is being conducted at multiple clinical sites in the United States and China.

THE PHASE IIb TRIAL

The Phase IIb Trial is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and serum phosphate-lowering effect of fixed-dose AP306 in patients with hyperphosphatemia receiving maintenance hemodialysis.

The Phase IIb Trial plans to enroll approximately 168 participants and randomize them across six fixed-dose AP306 regimens and placebo over an eight-week treatment period. The primary endpoint is the change in serum phosphate from baseline to the end of treatment, and the secondary endpoints include the proportion of participants reaching the target phosphate range and the time to phosphate control. Topline results of the Phase IIb Trial are expected in the first half of 2027.

ABOUT AP306

AP306 (formerly known as EOS789) is a first-in-class oral pan-phosphate transporter inhibitor in development for hyperphosphatemia in patients with chronic kidney disease receiving dialysis. AP306 inhibits three key intestinal phosphate transporters, NaPi-IIb, PiT-1, and PiT-2. AP306 was originally discovered by Chugai Pharmaceutical Co., Ltd. (“**Chugai**”) and was subsequently licensed to the Company, which has obtained the global rights to develop, manufacture and commercialize AP306. The National Medical Products Administration granted Breakthrough Therapy Designation to AP306 in June 2024.

In the completed Phase II clinical trial in China (ClinicalTrials.gov identifier: NCT05764590), AP306 monotherapy demonstrated a mean serum phosphate reduction of 2.51 mg/dL, greater than the 1.08 mg/dL reduction with the active comparator sevelamer carbonate, with nearly 95% of patients having their serum phosphate levels controlled at less than 5.5 mg/dL by Weeks 7 to 8, compared with approximately 50% in the sevelamer carbonate group over the same period. The most common adverse events were gastrointestinal disorders, mainly diarrhea, all of which were Grade 1/2 and mostly resolved within two weeks. No serious adverse events were reported in the AP306 group, and the discontinuation rate due to adverse events was less than 5%. The results of this trial were published in *Kidney International Reports* (2025;10:1143-1151; available at: <https://pubmed.ncbi.nlm.nih.gov/40303220/>).

COLLABORATION WITH R1

R1 Therapeutics, Inc. (“**R1**”) is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for patients with kidney disease. Under the collaboration and license agreement entered into by the Company and R1 in December 2025, the Company granted R1 an exclusive license to develop, manufacture, and commercialize AP306 outside the Chinese Mainland, Hong Kong, Macau, and Taiwan. The Company retains full rights and control over AP306 in those four markets. The Company and R1 are co-sponsors of the Phase IIb Trial. Each party is responsible for clinical trial execution and regulatory submissions in its respective territory and provides the other party with relevant data and support required for regulatory purposes.

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
*Chairman of the Board, executive Director and
Chief Executive Officer*

Hong Kong, July 21, 2026

As of the date of this announcement, the Board comprises (i) Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; (ii) Dr. Lu An as a non-executive Director; and (iii) Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.